Deciphera Pharmaceuticals AG

Deciphera is a biopharmaceutical company focused on the discovery, development and commercialization of important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch control kinase inhibitor platform and our deep expertise in kinase biology to develop a broad portfolio of innovative drugs. In addition to advancing several product candidates from our platform in clinical trials, QINLOCK® is Deciphera's fourth-generation switch control inhibitor for the treatment of GIST. Our commitment to patients is at the heart of everything we do.